Chenchen Zhao1,2, Xianbin Kong2, Shuang Han3, Xiaojiang Li1, Tong Wu4, Jie Zhou4, Yuzhu Guo5, Zhichao Bu2, Chuanxin Liu3, Chenning Zhang3,6, Yingjie Jia1. 1. Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88, Chang Ling Road, Li Qi Zhuang Jie, Xi Qing District, Tianjin 300381, PR China. 2. Graduate School, Tianjin University of Traditional Chinese Medicine, No. 10 Poyanghu Road, West Area, Tuanbo New Town, Jinghai District, Tianjin 301617, PR China. 3. School of Chinese Materia Medica, Beijing University of Chinese Medicine, Liangxiang Town, Fangshan District, Beijing 102488, PR China. 4. Department of Cardiology, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, No.69, Zeng Chan Road, He Bei district, Tianjin 300250, PR China. 5. Department of Oncology, Second Affliated Hospital of Tianjin University of Traditional Chinese Medicine, No.69, Zeng Chan Road, He Bei district, Tianjin 300250, PR China. 6. Institute of Wudang Traditional Chinese Medicine, Taihe hospital, Hubei University of Medicine, Remmin South Road 32, Shiyan City 442000, Hubei Province, PR China.
Abstract
Aim: Based on metabonomics, the metabolic markers of lung cancer patients were analyzed, combined with bioinformatics to explore the underlying disease mechanism. Materials & methods: Based on case-control design, using UPLC-Q-TOF/MS, urine metabolites were detected in discovery and validation set. Multivariate statistical analysis were performed to identify potential markers for lung cancer. A network analysis was constructed to integrate lung cancer disease targets with the above metabolic markers, and its possible mechanism and biological significance were explained. Results: A total of 35 potential markers were identified, 11 of which overlapped. Five key markers have a good linear correlation with serum biochemical indicators. Conclusion: The occurrence and development of lung cancer are closely related to disturbance of D-Glutamine and D-glutamate metabolism, amino acid imbalance. This test was registered on China clinical trial registration center (www.chictr.org.cn/index.aspx), registration number was ChiCTR1900025543.
Aim: Based on metabonomics, the metabolic markers of lung cancerpatients were analyzed, combined with bioinformatics to explore the underlying disease mechanism. Materials & methods: Based on case-control design, using UPLC-Q-TOF/MS, urine metabolites were detected in discovery and validation set. Multivariate statistical analysis were performed to identify potential markers for lung cancer. A network analysis was constructed to integrate lung cancer disease targets with the above metabolic markers, and its possible mechanism and biological significance were explained. Results: A total of 35 potential markers were identified, 11 of which overlapped. Five key markers have a good linear correlation with serum biochemical indicators. Conclusion: The occurrence and development of lung cancer are closely related to disturbance of D-Glutamine and D-glutamate metabolism, amino acid imbalance. This test was registered on China clinical trial registration center (www.chictr.org.cn/index.aspx), registration number was ChiCTR1900025543.